1. Chen, Yuanbing, Ning, Jieling, Shu, Long, Xia, Xuewei, Huang, Jun. 2024. CPLX2 is a novel tumor suppressor and improves the prognosis in glioma. In Journal of neuro-oncology, 167, 63-74. doi:10.1007/s11060-023-04548-4. https://pubmed.ncbi.nlm.nih.gov/38427133/
2. Li, Hui, Zhao, Juan, Zhong, Xiao-Lan, Zhang, Cheng-Fang, Cao, Tian-Sheng. 2022. CPLX2 Regulates Ferroptosis and Apoptosis Through NRF2 Pathway in Human Hepatocellular Carcinoma Cells. In Applied biochemistry and biotechnology, 195, 597-609. doi:10.1007/s12010-022-04135-9. https://pubmed.ncbi.nlm.nih.gov/36107387/
3. Peng, Qian, Wang, Lijiao, Wang, Shuling, Wang, Chenxu, Xue, Zhi. 2022. MicoRNA-214-3p: a key player in CPLX2-mediated inhibition on temozolomide resistance in glioma. In Neurological research, 44, 879-887. doi:10.1080/01616412.2022.2064699. https://pubmed.ncbi.nlm.nih.gov/36117461/
4. Komatsu, Hiroaki, Kakehashi, Anna, Nishiyama, Noritoshi, Suehiro, Shigefumi, Wanibuchi, Hideki. . Complexin-2 (CPLX2) as a potential prognostic biomarker in human lung high grade neuroendocrine tumors. In Cancer biomarkers : section A of Disease markers, 13, 171-80. doi:10.3233/CBM-130336. https://pubmed.ncbi.nlm.nih.gov/23912489/